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There is increasing interest in the search for accurate, repeatable and widely applicable clin-
ical biomarkers for the early detection of cardiometabolic alterations and oxidative status.
Viscosity is a promising tool in that sense, although most studies have used simple visco-
simeters, providing limited information, and have not considered oxidative status. The aim
of this study was to assess whether viscosity determinations were associated with cardio-
metabolic and oxidative status in subjects at a primary stage of cardiometabolic risk. A pilot
study (n = 20) was conducted in subjects with abdominal obesity, determining urine and
plasma viscosity with a rotational rheometer at different shear rates (10000–1000 s–1 in
plasma and 1000–50 s–1 in urine). Simple regression showed that urine viscosity was signifi-
cantly (p< 0.05) associated with markers of oxidative status, and plasma viscosity with
blood glucose. Categorical Principal Component Analysis plots showed that urine viscosity
measurements at different shear rates clustered in three groups (low, intermediate and high
shear rates) were selectively associated with uric acid, polyphenols and antioxidant capacity
respectively. Plasma viscosity did not seem to be a relevant clinical marker in subjects with
abdominal obesity. Therefore, urine viscosity could potentially serve as a complimentary
marker in the evaluation of oxidative status.
Introduction
Non-communicable diseases such as cardiometabolic pathologies are among the most fre-
quent causes of death, a trend which is expected to increase in coming years [1]. These pathol-
ogies, or previous high risk situations, are commonly diagnosed based on a combination of
biochemical and anthropometric parameters; such is the case of metabolic syndrome, where
several criteria must be simultaneously fulfilled [2] implying several determinations. Besides,
oxidative status is known to be impaired in cardiometabolic pathologies [3]. Nevertheless, its
evaluation also comprises different measurements, from the activity of antioxidant enzymes to
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concentrations of specific oxidized biomolecules [4], some of them difficult to apply routinely
to large sample batches and to be very laborious techniques. Therefore, the practical problems
associated with all these determinations on a large scale are driving the search for new cheap,
widely applicable clinical biomarkers.
Rheology is based on the evaluation of flow and deformation responses of a substance when
subjected to stress [5]. Specifically, viscosity is the resistance of a fluid to a deforming force by
either shear or tensile stress. It provides information about the microstructure and properties
of a fluid or soft material and is usually shear-rate dependent in non-Newtonian fluids [6].
Therefore, taking into account that differences in chemical and molecular composition of bio-
logical samples affected viscosity, it is thought that this property could be linked to clinical risk
factors.
In the case of blood, viscosity depends on haematocrit, erythrocytes deformability and
plasma viscosity, which in turn depends mostly on its protein profile. Since different patholo-
gies (from rheumatoid arthritis to angina pectoris) are associated with modifications in these
parameters, blood or plasma viscosity–depending on the case- have been proposed as a marker
for them [7]. In the particular context of cardiometabolic diseases, this measurement has been
shown to be significantly increased in subjects with already-diagnosed metabolic syndrome or
in old subjects [8], but it has been less studied at previous risk stages. In these studies viscosity
was determined with simple viscometers such as capillary [7,9] or cone-plate viscometers
[8,10], based on the assumption that plasma was a Newtonian fluid (not depending on flow
characteristics) [7]. On the contrary, other authors [11–13] have reported non-Newtonian
behaviour of whole blood and the importance of a detailed rheological characterization of this
fluid. In particular, the characterization of blood flow behaviour and of the distribution of the
wall shear stress in small vessels may help detect cardiovascular diseases and design suitable
treatments [14], suggesting the use of a rotational rheometer within a wide range of shear
rates. Nevertheless, this kind of rotational rheometer has been scarcely used up to date.
In the case of urine, some studies have examined viscosity or other related parameters in
healthy individuals or in certain pathological situations [15–17] as possible early clinical mark-
ers. However, all these studies have assumed that urine is a Newtonian fluid, although to the
author’s knowledge there is no work justifying this statement. Finally, only one study has
explored the potential association between viscosity of biological samples and oxidative status
[10]. The authors just cited found an increase in plasma viscosity in subjects with increased
oxidative stress (measured as malondialdehyde), but in a very specific population, i.e., subjects
with severe obstructive sleep apnea syndrome.
Therefore, the aim of this study was to evaluate whether plasma and urine viscosity deter-
minations in subjects at a primary stage of cardiometabolic risk were associated with clinical
risk factors as well as with oxidative status. To this end, a pilot clinical trial (n = 20) was con-
ducted in subjects with abdominal obesity. New findings regarding the association between
urine viscosity and oxidative status were obtained.
Methods
Subjects
Subjects were participating in a study on the effects of grape and pomegranate polyphenols on
cardiometabolic risk factors and oxidative status, where viscosity was included as a related
measurement. The cardiometabolic criteria for inclusion in the study was abdominal obesity,
defined as abdominal diameter> 94 cm for men and> 80 cm for women [2]- although other
anthropometric parameters were also measured, as explained below. Besides, the subjects
should be apparently healthy; not medicated for cardiometabolic pathologies; and aged
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between 40 and 60 years. Exclusion criteria were: pregnant or lactating; previously diagnosed
with a chronic disease (cardiovascular diseases, inflammatory diseases, diabetes or cancer);
any regular pharmaceutical treatment or nutritional supplements; participating in any other
dietary intervention study.
This study was approved by the Ethics Subcommittee of the CSIC, Madrid, Spain (2015/12/
21) and the Ethics Committee for Clinical Research of the University Hospital Puerta de
Hierro-Majadahonda, Majadahonda, Spain (2015/11/23). It was registered in the Clinical Tri-
als database (NCT02710461). The study was conducted between February and June 2016 at
the Unit of Human Nutrition of the ICTAN-CSIC. All the subjects signed a written consent
form agreeing to participate in the study.
A total of 20 subjects, 10 male and 10 female, participated in the study. Besides the nutri-
tional intervention they later followed, this sample size was considered as appropriate for the
evaluation of the association between plasma and urine viscosity with cardiometabolic bio-
markers at baseline, based on a previous study defining an association between Body Mass
Index (BMI) and plasma viscosity [18], and considering an 80% power and an unilateral alpha
value of 0.05. All subjects fulfilled the criteria for abdominal obesity (mean values, 110 ± 9 cm
for males, 100 ± 9 for females) and, based on body mass index (BMI) values, 35% were over-
weight and 40% were obese (mean BMI, 29.7 ± 2.7). Additionally, 50% exhibited a waist-to-
hip ratio (WHR) above recommendations (mean values, 0.98 ± 0.09 for males, 0.84 ± 0.13 for
females) [19]. Regarding cardiometabolic risk factors [2], 25% of the subjects showed high sys-
tolic pressure (< 130 mm Hg), 50% high diastolic pressure (> 85 mm Hg), 15% high triglycer-
ides (> 150 mg/dL), 20% low high-density lipoprotein (HDL)-cholesterol (< 50 mg/dL for
women and 40 mg/dL for men), 60% high low-density lipoprotein (LDL)-cholesterol (> 130
mg/dL) and 55% high total cholesterol (> 200 mg/dL). Further details on the subjects have
been reported elsewhere[20]. The present study is based on baseline determinations in these
subjects, independently of the treatments they followed later as part of the mentioned nutri-
tional intervention study.
Biological samples
Samples used for the present study conformed to basal values of the clinical study, so the vol-
unteers had not received any supplementation. Fasting venous blood samples were collected in
tubes with sodium heparin as anticoagulant, centrifuged, and plasma was recovered. Fasting
urine was recovered 0–3 h after arrival at the Unit of Human Nutrition of the ICTAN-CSIC
first thing in the morning. Plasma and urine samples were stored at -80˚C until analysis.
Subjects followed their normal lifestyle, although seventy-two hours prior to sample collec-
tion, they were required to refrain from consumption of polyphenol-rich foods due to the fur-
ther supplementation they were going to receive; since this was a very punctual modification
of their dietary habits, it may be excluded that it affected the biochemical measurements car-
ried out in the samples, or the viscosity determinations.
Viscosity measurements
Viscosity was measured in a Kinexus pro rheometer (Malvern Instruments Ltd., Worcester-
shire, UK) equipped with a cone-plate of 60 mm diameter, 1˚ angle and a gap of 0.030 mm.
One millilitre of urine or 100 μL of plasma (1:15 dilution) was placed with a pipette on a pre-
heated plate (37˚C). Temperature was controlled to within 0.1˚C by Peltier elements in the
lower plate. A temperature cover was used to maintain the samples at the specified tempera-
ture (37˚C) and prevent evaporation. To homogenize mechanical equilibrium before measure-
ments, all the samples were put through a pre-shearing test for one min at 100 s–1, 37˚C. Flow
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curves were then plotted as a function of shear rate ranging from 1000 to 50 s–1 for urine sam-
ples and from 10000 to 1000 s–1 for plasma samples. At least three flow curves were made for
each individual choosing the shear rates more convenient for each biological sample to obtain
proper correlations of flow curves. Viscosities were taken at nine different descending shear
rates by decade for statistical analysis of the flow curves.
Biochemical determinations
Regarding cardiometabolic biomarkers, blood glucose was determined using a glucometer
from Abbott (Chicago, IL, USA). Plasma insulin was determined with an ELISA kit (Millipore,
MA, USA). Lipid profile was measured by standard automated methodologies.
For oxidative status evaluation, Plasma and urine uric acid were determined using an enzy-
matic-colorimetric kit (Spin React, San Esteve de Bas, Girona, Spain). Blood and urine antioxi-
dant capacity were estimated using the ferric reducing ability of plasma (FRAP) and 2,2’-
azinobis(3-ethylbenzothiazoline-sulfonic acid (ABTS) assays [21–23]. The Folin-Ciocalteu
assay was used after solid phase extraction to evaluate the polyphenol content of urine [24].
All urine measurements were normalized using creatinine concentration, measured via the
colorimetric Jaffe reaction. The values recorded in these determinations, detailed elsewhere
[20], were used to evaluate correlations with viscosity measurements.
Statistical analysis
Data were analysed with the statistical SPSS IBM 19 package for Windows. First, normal data
distribution was evaluated and data on urine viscosity at 398 and 1000 s–1 were log trans-
formed. For comparing the values obtained at the different shear rates, one-way ANOVA fol-
lowed by post-hoc Tukey test were applied. Pearson correlation coefficients were calculated to
examine the relationship between urine and plasma viscosities and cardiometabolic risk fac-
tors. In this way the variables correlating with plasma or urine viscosity were identified and
then used in categorical principal components analysis (CATPCA). Additionally, and in order
to discard the possible confounding role of age and central obesity on oxidative stress results,
Factorial Principal Component Analysis was performed including viscosity and these vari-
ables. Similarly, Partial Correlation Analysis adjusted by age and central obesity measures was
performed. These tests were only carried out for urine values since in blood no association
between these variables was found.
Results
Fig 1 shows the median viscosity and the upper and lower whiskers values in urine (A) and
plasma (B) from subjects with abdominal obesity. Different shear ranges were taken for each
fluid (10000–1000 s–1 in plasma and 1000–50 s–1 in urine) given the probable differences in
biochemical composition of the two fluids. Indeed, viscosity values in plsma were higher than
in urine. Regarding values at most shear rates, no significant differences were observed in
urine, with only those at 1000 s–1 being higher than the rest (p< 0.05); in contrast, significant
differences between most shear rates (p< 0.05) were found in plasma. In a higher shear rate
range, plasma samples (Fig 1B) showed well-defined non-Newtonian shear-thinning, with vis-
cosity values decreasing from 8.68 ± 1.77 to 1.28 ± 0.270 mPa s with increasing shear rate from
1000 to 10000 s–1. On the contrary, in a lower shear rate range, urine viscosity trends to
increase with increasing shear rate (Fig 1A) from 1.38 ± 0.860 up to 4.07 ± 3. 05 mPa s between
100 and 1000 s–1, although values at the lowest shear rate (50 s–1) were intermediate and close
to those obtained at 200 s–1 (1.64 ± 1.09 and 1.62 ± 1.09 mPa s, respectively). Individual viscos-
ity values for all the subjects are shown in S1 Table and S2 Table.
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Correlation coefficients between urine and plasma viscosities and cardiometabolic risk fac-
tors are shown in Tables 1 and 2 respectively; individual values for cardiometabolic risk factors
are shown in S3 Table, S4 Table and S5 Table. At eight of the selected shear rates, urine viscos-
ity correlated significantly either with age or with antioxidant capacity (TEAC) (Table 1).
However, age did not correlate with urine viscosity at 100 and 50 s–1 respectively. On the other
hand, at both 100 and 50 s–1, urine viscosity also correlated significantly with polyphenols.
These associations were kept when Partial Correlation Analysis adjusted by age and central
obesity measures (abdominal perimeter, WHR, WST) was performed. On the contrary, the
observed significant association between urine viscosity and uric acid (at shear rate of 50) was
lost when Partial Correlation Analysis was adjusted by age, being therefore mediated by this
parameter. For its part, plasma viscosity was only found to correlate with glucose (Table 2).
Fig 1. Viscosity values (mPa s) of human urine and plasma from subjects with abdominal obesity at different shear
rates (s–1) selected from flow curves; (A) urine; (B) plasma. Different superscript letter indicate significant differences
(P< 0.05) between shear rates.
https://doi.org/10.1371/journal.pone.0204075.g001
Table 1. Correlations (R and p values) among diverse cardiometabolic risk factors and viscosity measurements at different shear rates (s-1) in human urine.
Shear rate (s–1)
1000 398 200 159 126 100 79 63 50
Anthropometry



















Abdominal perimeter -0.056 -0.025 -0.101 -0.031 -0.075 0.000 0.045 0.095 0.125
BMI -0.068 -0.046 -0.012 0.022 -0.003 0.027 0.047 0.074 0.087
WHR -0.190 -0.179 -0.353 -0.208 -0.285 -0.117 -0.015 0.081 0.151
WSR -0.195 -0.174 -0.277 -0.179 -0.238 -0.127 -0.053 0.019 0.069
Biochemistry
Uric Acid -0.450 -0.071 0.073 0.003 0.038 0.413 0.086 0.122 0.467
Polyphenols 0.190 0.194 0.364 0.336 0.349 0.677
(0.001)
0.274 0.242 0.701 (0.001)
Antioxidant capacity
(FRAP)
0.198 0.181 0.184 0.149 0.160 0.113 0.116 0.099 0.132
Antioxidant capacity
(TEAC)
0.693 (0.001) 0.668 (0.001) 0.736 (0.000) 0.664 (0.010) 0.702 (0.010) 0.617
(0.040)
0.546 (0.013) 0.470 (0.037) 0.478
Significant correlations (p 0.05) are given in boldface. BMI, body mass index; WHR, waist-to-hip ratio; WSR, waist-to-stature ratio; FRAP, ferric reducing antioxidant
power; TEAC, trolox equivalent antioxidant.
https://doi.org/10.1371/journal.pone.0204075.t001
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CATPCA accounts for almost 85% of the variance of the variables under analysis in the case
of urine, and for 92% in the case of plasma, indicating the goodness of the fits of the compo-
nents for both biological fluids (Table 3). Also, the first two dimensions for each cardiometa-
bolic risk factor are shown in urine (Fig 2A) and plasma (Fig 2B). Both biplots overlap the
Table 2. Correlations (R and p values) among diverse cardiometabolic risk factors and viscosity measurements at different shear rates (s-1) in human plasma.
Shear rate (s–1)
10000 7944 6310 5012 3981 3162 2512 1585 1000
Anthropometry
Sex 0.123 0.118 0.134 0.130 0.128 0.130 0.074 0.091 0.068
Age 0.283 0.260 0.300 0.298 0.301 0.325 0.341 0.336 0.325
Abdominal perimeter -0.269 -0.257 -0.261 -0.243 -0.232 -0.243 -0.206 -0.240 -0.241
BMI 0.071 0.088 0.058 0.072 0.077 0.066 0.095 0.075 0.087
WHR -0.125 -0.096 -0.085 -0.065 -0.054 -0.063 -0.074 -0.134 -0.140
WSR 0.103 0.118 0.122 0.140 0.151 0.143 0.139 0.083 0.087
Systolic pressure 0.186 0.210 0.223 0.224 0.205 0.191 0.215 0.199 0.224
Diastolic pressure 0.047 0.036 0.007 0.014 0.001 -0.025 0.015 0.025 0.061
Biochemistry
Triglycerides 0.326 0.361 0.363 0.380 0.366 0.354 0.392 0.417 0.421
HDL-cholesterol -0.005 -0.001 0.018 0.005 0.021 0.040 -0.005 0.007 0.034
LDL-cholesterol 0.070 0.063 0.087 0.076 0.075 0.071 0.014 0.032 0.023



















Insuline 0.210 0.267 0.270 0.292 0.312 0.306 0.362 0.335 0.340
HOMA index 0.269 0.328 0.331 0.352 0.372 0.369 0.421 0.393 0.406
HOMA-beta index -0.112 -0.048 -0.042 -0.026 -0.005 -0.014 0.035 0.012 0.012
Quicky index -0.158 -0.225 -0.231 -0.253 -0.265 -0.251 -0.296 -0.271 -0.255
Uric Acid 0.186 0.227 0.211 0.215 0.221 0.218 0.251 0.245 0.241
Antioxidant capacity (FRAP) 0.187 0.229 0.214 0.218 0.224 0.221 0.253 0.247 0.243
Antioxidant capacity
(TEAC)
-0.376 -0.374 -0.363 -0.375 -0.364 -0.369 -0.331 -0.356 -0.369
Significant correlations (p 0.05) are given in boldface. BMI, body mass index; WHR, waist-to-hip ratio; WSR, waist-to-stature ratio; HOMA, homeostatic model
assessment; FRAP, ferric reducing antioxidant power; TEAC, trolox equivalent antioxidant capacity.
https://doi.org/10.1371/journal.pone.0204075.t002
Table 3. Summary of categorical principal components analysis. (CATPCA) for human urine and plasma.
Urine CATPCA model
Dimension Cronbach’s alpha Variance
Total (eigenvalue) % of variance
1 0.970 9.01 75.1
2 0.138 1.15 9.54
Total 0.984a 10.2 84.6
Plasma CATPCA model
1 0.985 11.1 85.2
2 -0.069 0.940 7.23
Total 0.993a 12.0 92.4
a Cronbach’s alpha means is based on the mean of the eigenvalue.
https://doi.org/10.1371/journal.pone.0204075.t003
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shear rates (indicated by points) and the component loadings (of each item, indicated by vec-
tors) form CATPCA along both dimensions. The coordinates of the end point of each vector
are given by the loadings of each variable on the first and second components. Long vectors
indicate good fit. The cosines of the angles between the vectors equal the correlations between
the quantified variables. It can be observed that in scatterplots for both biological fluids,
dimension 1 is able to capture more of the variance than dimension 2. In the case of urine (Fig
2A), viscosity measurements at different shear rates are clustered in three groups (low, inter-
mediate and high shear rates) associated with uric acid, polyphenols and antioxidant capacity
respectively. On the other hand, all viscosity values are clustered together (Fig 2B).
Discussion
The present study aimed to evaluate the usefulness of viscosity measurements in biological flu-
ids as a way to integrate several parameters of cardiometabolic risk and associated altered oxi-
dative status in subjects in the early stages of cardiometabolic risk. This might serve as a
strategy in prior screening of subjects or in large-scale population studies, in order to decide in
which cases detailed biochemical determinations should be adopted later on. To this end, a
pilot study (n = 20) was conducted in subjects with abdominal obesity, determining urine and
plasma viscosity with a rotational rheometer which makes it possible to characterize the flow
over a wide shear rate range (from 50 to 1000 s-1 and 1000 to 10000 s-1 respectively). Overall,
the viscosity values were in the same range as previously reported in other studies [13,16]. Sim-
ilarly, some of the results agree with previous ones, such as the lack of association between
plasma viscosity and age or gender [7].
Nevertheless, in this study, unlike previous ones based on the use of simple viscometers, a
rheometer with a range of shear rates was applied, with the object of assessing the potential dif-
ferential information provided by different shear rates in subjects in the early stages of cardio-
metabolic disorders. Interestingly, a previous study on the association of plasma viscosity and
lipid profile also observed that specific shear rates were associated with different physiological
characteristics [25]. The present results indicate that while values in plasma viscosity
decreased, urine viscosity tended to increase as shear rates increased.
Whole blood is well characterized in the literature in terms of steady shear rheology, and
flow curves have been published identifying several erythrocyte characteristics as the main
contributing factors to its viscosity [13,26,27]. For its part, plasma is a highly concentrated pro-
tein solution, and therefore weak protein-protein interactions could play an important role in
Fig 2. Categorical principal components analysis (CATPCA) in samples from subjects with abdominal obesity; (A)
Biplot-CATPCA urine; (B) Biplot-CATPCA-Plasma. Numbers are representing different shear rates used to determine
viscosity at each biological fluid.
https://doi.org/10.1371/journal.pone.0204075.g002
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the viscosity of this fluid. Despite promising results on the clinical relevance of plasma viscos-
ity, this fluid has been less studied than blood viscosity [7]. Indeed, it has been suggested that
plasma viscosity may be more sensitive than blood viscosity to changes in the plasma proteins
associated with cardiovascular disease risk and mortality, and hence would be more valid as a
clinical marker of these situations [9]. Therefore, plasma viscosity rather than blood viscosity
was evaluated in the present study. Nevertheless, both simple regression and CATPCA plots
(Table 2 and Fig 2B) indicated that at all the tested shear rates plasma viscosity values were pos-
itively associated with blood glucose but not with any of the other parameters evaluated. There
are easy and cheap quantitative methods to determine blood glucose, so given that this was the
only association found, results from the present study indicate that viscosity measurement in
plasma is not clinically relevant to cardiometabolic risk or oxidative status in subjects with
abdominal obesity. This conflicts with a previous study, in which the authors found associa-
tions between plasma viscosity and all components of metabolic syndrome but glucose [8]
although in this case the subjects already exhibited metabolic syndrome.
On the other hand, several significant associations were detected between viscosity mea-
surements in urine, although these are not associated with cardiometabolic risk, and oxidative
status (Fig 2A). In particular, CATPCA plots showed that the lowest shear rates tested (50 and
63 s–1) were associated with urine uric acid, the intermediate rates (100 and 156 s–1) with urine
polyphenols and the highest (398 and 1000 s–1) with urine antioxidant capacity, as determined
by TEAC assay. Inverse associations have been reported between increased antioxidant capac-
ity in biological fluids and several cardiometabolic risk factors [28,29]. Nevertheless, in vivo
antioxidant capacity is known to be derived from different constituents: a) polyphenols, phyto-
chemicals increased levels of which in urine have also been associated with health benefits
[30,31], b) uric acid, a well-described marker of cardiovascular risk [32]. Indeed, antioxidant
capacity values are commonly reported after subtracting the contribution of uric acid, i.e.,
reporting only that of polyphenols [33]. Therefore, the results of this pilot study suggest that
urine viscosity at several shear rates may be used as a first screening tool for different compo-
nents of oxidative status. Nevertheless, the previously mentioned potential confounding role
of age regarding the association between urine viscosity and uric acid should not be disre-
garded. Therefore, these results should be confirmed in a wider population, since at this time
there is a scarcity of human urine viscosity measurements.
In conclusion, a pilot study was conducted in subjects with abdominal obesity to evaluate
the usefulness of viscosity measurements in urine and plasma as indicators of cardiometabolic
risk and oxidative status in this population. Plasma viscosity did not seem to be relevant in this
connection, but significant associations were detected between urine viscosity and oxidative
status. In particular, urine viscosity measured at different shear rates (from 50 to 1000 s–1) was
selectively associated with urine antioxidant capacity, polyphenols and uric acid. This indicates
a potential for urine viscosity to be used as a complimentary marker in the evaluation of oxida-
tive status, something that needs to be confirmed in wider populations.
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supplement from grape and pomegranate in postprandial blood glucose and related parameters in sub-
jects with abdominal obesity. 18th International Congress of Food Science and Technology, Dublin,
2016, 202.
21. Benzie IFF, Strain JJ Ferric reducing/antioxidant power assay: Direct measure of total antioxidant activ-
ity of biological fluids and modified version for simultaneous measurement of total antioxidant power
and ascorbic acid concentration. Anal Biochem 1996; 239: 70–76. https://doi.org/10.1006/abio.1996.
0292 PMID: 8660627
22. Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an
improved ABTS radical cation decolorization assay. Free Radical Biol Med 1999; 26: 1231–1237.
23. Pulido R, Bravo L, Saura-Calixto F Antioxidant activity of dietary polyphenols as determined by a modi-
fied ferric reducing/antioxidant power assay. J Agric Food Chem 2000; 48: 3396–3402. PMID:
10956123
24. Roura E, Andrés-Lacueva C, Estruch R, Lamuela-Raventós RM Total polyphenol intake estimated by a
modified folin-ciocalteu assay of urine. Clinical Chem 2006; 52: 749–752.
25. Yang T, Doherty J, Zhao B, Kinchla AJ, Clark JM, He L. Effectiveness of Commercial and Homemade
Washing Agents in Removing Pesticide Residues on and in Apples. J Agric Food Chem 2017; 65:
9744–9752. https://doi.org/10.1021/acs.jafc.7b03118 PMID: 29067814
26. Osterode W Hemorheology in occupational lead exposure. Scand J Work Environment Health 1996;
22: 369–373.
27. Kim S, Cho YI, Hogenauer WN, Kensey KR A method of isolating surface tension and yield stress
effects in a U-shaped scanning capillary-tube viscometer using a casson model. J Non-Newtonina Fluid
Mechanics 2002; 103: 205–219.
28. Skalska AB, Pietrzycka A, Stepniewski M Correlation of endothelin 1 plasma levels with plasma antioxi-
dant capacity in elderly patients treated for hypertension. Clinical Biochem 2009; 42: 358–364.
29. Razquin C, Martinez JA, Martinez-Gonzalez MA, Mitjavila MT, Estruch R, Martı́ A. A 3 years follow-up
of a Mediterranean diet rich in virgin olive oil is associated with high plasma antioxidant capacity and
reduced body weight gain. Eur J Clin Nutr 2009; 63: 1387–1393. https://doi.org/10.1038/ejcn.2009.106
PMID: 19707219
30. Guo X, Tresserra-Rimbau A, Estruch R, Martı́nez-González MA, Medina-Remón A, Castañer O. Effects
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